Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05980806 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05980806 · ClinicalTrials.gov record · last posted 2026-02-12

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Name: A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia — clinical trial record (NCT05980806)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SENTRY-2

StatusRecruiting

PhasePhase 2

SponsorKaryopharm Therapeutics Inc

Started2024-04-22

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.

Amendment record 9 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 9 times since 2023-07-31; most recent amendment 2026-02-10. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-06-03

Status change Not Yet Recruiting→Recruitingv5

Trial Details

NCT Number	NCT05980806
Lead Sponsor	Karyopharm Therapeutics Inc
Conditions	Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
Enrollment	58 participants
Start Date	2024-04-22
Primary Completion	2027-06 (estimated)
Study Completion	2028-10 (estimated)
Updated on ClinicalTrials.gov	2026-02-12